4.6 Article

Slaying the Trojan Horse: Natural Killer Cells Exhibit Robust Anti-HIV-1 Antibody-Dependent Activation and Cytolysis against Allogeneic T Cells

Journal

JOURNAL OF VIROLOGY
Volume 89, Issue 1, Pages 97-109

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.02461-14

Keywords

-

Categories

Funding

  1. National Health and Medical Research Council (NHMRC) [510448]
  2. Canadian Institutes of Health Research (CIHR)

Ask authors/readers for more resources

Many attempts to design prophylactic human immunodeficiency virus type 1 (HIV-1) vaccines have focused on the induction of neutralizing antibodies (Abs) that block infection by free virions. Despite the focus on viral particles, virus-infected cells, which can be found within mucosal secretions, are more infectious than free virus both in vitro and in vivo. Furthermore, assessment of human transmission couples suggests infected seminal lymphocytes might be responsible for a proportion of HIV-1 transmissions. Although vaccines that induce neutralizing Abs are sought, only some broadly neutralizing Abs efficiently block cell-to-cell transmission of HIV-1. As HIV-1 vaccines need to elicit immune responses capable of controlling both free and cell-associated virus, we evaluated the potential of natural killer (NK) cells to respond in an Ab-dependent manner to allogeneic T cells bearing HIV-1 antigens. This study presents data measuring Ab-dependent anti-HIV-1 NK cell responses to primary and transformed allogeneic T-cell targets. We found that NK cells are robustly activated in an anti-HIV-1 Ab-dependent manner against allogeneic targets and that tested target cells are subject to Ab-dependent cytolysis. Furthermore, the educated KIR3DL1(+) NK cell subset from HLA-Bw4(+) individuals exhibits an activation advantage over the KIR3DL1(-) subset that contains both NK cells educated through other receptor/ligand combinations and uneducated NK cells. These results are intriguing and important for understanding the regulation of Ab-dependent NK cell responses and are potentially valuable for designing Ab-dependent therapies and/or vaccines. IMPORTANCE NK cell-mediated anti-HIV-1 antibody-dependent functions have been associated with protection from infection and disease progression; however, their role in protecting from infection with allogeneic cells infected with HIV-1 is unknown. We found that HIV-1-specific ADCC antibodies bound to allogeneic cells infected with HIV-1 or coated with HIV-1 gp120 were capable of activating NK cells and/or trigging cytolysis of the allogeneic target cells. This suggests ADCC may be able to assist in preventing infection with cell-associated HIV-1. In order to fully utilize NK cell-mediated Ab-dependent effector functions, it might also be important that educated NK cells, which hold the highest activation potential, can become activated against targets bearing HIV-1 antigens and expressing the ligands for self-inhibitory receptors. Here, we show that with Ab-dependent stimulation, NK cells expressing inhibitory receptors can mediate robust activation against targets expressing the ligands for those receptors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cell Biology

Circulating effector γδ T cell populations are associated with acute coronavirus disease 19 in unvaccinated individuals

Anouk von Borstel, Thi H. O. Nguyen, Louise C. Rowntree, Thomas M. Ashhurst, Lilith F. Allen, Lauren J. Howson, Natasha E. Holmes, Olivia C. Smibert, Jason A. Trubiano, Claire L. Gordon, Allen C. Cheng, Stephen J. Kent, Jamie Rossjohn, Katherine Kedzierska, Martin S. Davey

Summary: SARS-CoV-2 infection can cause severe COVID-19 in some individuals. The immune system, particularly effector gamma delta T cells, plays a role in the defense against SARS-CoV-2. Our study shows an association between effector populations of gamma delta T cells and acute COVID-19 in unvaccinated individuals.

IMMUNOLOGY AND CELL BIOLOGY (2023)

Correction Immunology

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2 (vol 13, 889372, 2022)

Bruce D. Wines, Liriye Kurtovic, Halina M. Trist, Sandra Esparon, Ester Lopez, Klasina Chappin, Li-Jin Chan, Francesca L. Mordant, Wen Shi Lee, Nicholas A. Gherardin, Sheila K. Patel, Gemma E. Hartley, Phillip Pymm, James P. Cooney, James G. Beeson, Dale I. Godfrey, Louise M. Burrell, Menno C. van Zelm, Adam K. Wheatley, Amy W. W. Chung, Wai-Hong Tham, Kanta Subbarao, Stephen J. Kent, P. Mark Hogarth

FRONTIERS IN IMMUNOLOGY (2023)

Article Computer Science, Artificial Intelligence

DAACO: adaptive dynamic quantity of ant ACO algorithm to solve the traveling salesman problem

Huijun Liu, Ao Lee, Wenshi Lee, Ping Guo

Summary: This study proposes a dynamic adaptive ACO (DAACO) algorithm to solve the TSP problem. DAACO introduces diversity in the initialization of the ACO algorithm by dynamically determining the number of ants to prevent local optimization. It also adopts a hybrid local selection strategy to improve the quality of optimization and reduce the time required. Experimental results demonstrate that the DAACO algorithm outperforms existing state-of-the-art ACO algorithms in terms of convergence time, solution quality, and average value on the TSPLIB dataset.

COMPLEX & INTELLIGENT SYSTEMS (2023)

Article Immunology

Cytokines enhance human Vγ9Vδ2 T-cell TCR-dependent and TCR-independent effector functions

Kirsty R. Field, Kathleen M. Wragg, Wen Shi Lee, Marc Rigau, Adam P. Uldrich, Stephen J. Kent, Jennifer A. Juno

Summary: V?9Vd2 T cells can recognize various molecules associated with cellular stress or transformation, providing a unique avenue for the treatment of cancers or infectious diseases. Enhancing the cytotoxic effector function of V?9Vd2 T cells is one potential avenue through which the immunotherapeutic potential of this subset may be improved.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Article Immunology

SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses

Marios Koutsakos, Arnold Reynaldi, Wen Shi Lee, Julie Nguyen, Thakshila Amarasena, George Taiaroa, Paul Kinsella, Kwee Chin Liew, Thomas Tran, Helen E. Kent, Hyon-Xhi Tan, Louise C. Rowntree, Thi H. O. Nguyen, Paul G. Thomas, Katherine Kedzierska, Jan Petersen, Jamie Rossjohn, Deborah A. Williamson, David Khoury, Miles P. Davenport, Stephen J. Kent, Adam K. Wheatley, Jennifer A. Juno

Summary: By analyzing the cellular immune response in previously vaccinated individuals infected with Delta or Omicron variants of SARS-CoV-2, researchers found that spike-specific CD4+ and CD8+ memory T cells were rapidly activated and contributed to the control of viral replication.

IMMUNITY (2023)

Letter Virology

Statement in Support of: Virology under the Microscope-a Call for Rational Discourse

Peter Speck, Jason Mackenzie, Rowena A. Bull, Barry Slobedman, Heidi Drummer, Johanna Fraser, Lara Herrero, Karla Helbig, Sarah Londrigan, Gregory Moseley, Natalie Prow, Grant Hansman, Robert Edwards, Chantelle Ahlenstiel, Allison Abendroth, David Tscharke, Jody Hobson-Peters, Robson Kriiger-Loterio, Rhys Parry, Glenn Marsh, Emma Harding, David A. Jacques, Matthew J. Gartner, Wen Shi Lee, Julie McAuley, Paola Vaz, Frank Sainsbury, Michelle D. Tate, Jane Sinclair, Allison Imrie, Stephen Rawlinson, Andrew Harman, Jillian M. Carr, Ebony A. Monson, Merilyn Hibma, Timothy J. Mahony, Thomas Tu, Robert J. Center, Lok Bahadur Shrestha, Robyn Hall, Morgyn Warner, Vernon Ward, Danielle E. Anderson, Nicholas S. Eyre, Natalie E. Netzler, Alison J. Peel, Peter Revill, Michael Beard, Alistair R. Legione, Alexandra J. Spencer, Adi Idris, Jade Forwood, Subir Sarker, Damian F. J. Purcell, Nathan Bartlett, Joshua M. Deerain, Bruce J. Brew, Sassan Asgari, Helen Farrell, Alexander Khromykh, Daniel Enosi Tuipulotu, David Anderson, Sevim Mese, Yaman Tayyar, Kathryn Edenborough, Jasim Muhammad Uddin, Abrar Hussain, Connor J. I. Daymond, Jacinta Agius, Karyn N. Johnson, Paniz Shirmast, Mahdi Abedinzadeshahri, Robin MacDiarmid, Caroline L. Ashley, Jay Laws, Lucy L. Furfaro, Thomas D. Burton, Stephen M. R. Johnson, Zahra Telikani, Mary Petrone, Justin A. Roby, Carolyn Samer, Andreas Suhrbier, April van der Kamp, Anthony Cunningham, Celeste Donato, Jackie Mahar, Wesley D. Black, Subhash Vasudevan, Roman Lenchine, Kirsten Spann, Daniel J. Rawle, Penny Rudd, Jessica Neil, Richard Kingston, Timothy P. Newsome, Ki Wook Kim, Johnson Mak, Kym Lowry, Nathan Bryant, Joanne Meers, Jason A. Roberts, Nigel McMillan, Larisa I. Labzin, Andrii Slonchak, Leon E. Hugo, Bennett Henzeler, Natalee D. Newton, Cassandra T. David, Patrick C. Reading, Camille Esneau, Tatiana Briody, Najla Nasr, Donna McNeale, Brian McSharry, Omid Fakhri, Bethany A. Horsburgh, Grant Logan, Paul Howley, Paul Young

JOURNAL OF VIROLOGY (2023)

Article Biochemistry & Molecular Biology

Predicting the efficacy of variant-modified COVID-19 vaccine boosters

David S. Khoury, Steffen S. Docken, Kanta Subbarao, Stephen J. Kent, Miles P. Davenport, Deborah Cromer

Summary: Booster vaccination is necessary to combat waning immunity and variants of SARS-CoV-2. Data on neutralization titers from multiple sources suggest that using ancestral vaccines can enhance protection against symptomatic and severe disease caused by variant viruses. Variant-modified vaccines may provide additional benefits. This study provides evidence-based guidance for future COVID-19 vaccine regimens.

NATURE MEDICINE (2023)

Article Multidisciplinary Sciences

Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis

Deborah Cromer, Megan Steain, Arnold Reynaldi, Timothy E. Schlub, Shanchita R. Khan, Sarah C. Sasson, Stephen J. Kent, David S. Khoury, Miles P. Davenport

Summary: The study demonstrates a strong correlation between neutralising antibody titres and vaccine effectiveness against symptomatic and severe COVID-19. Predicted neutralising antibody titres are strongly correlated with observed vaccine effectiveness, and the loss of neutralising antibodies over time and to new variants is predictive of observed vaccine protection against severe COVID-19.

NATURE COMMUNICATIONS (2023)

Article Engineering, Biomedical

Engineered Ferritin Nanoparticle Vaccines Enable Rapid Screening of Antibody Functionalization to Boost Immune Responses

Mai N. Vu, Emily H. Pilkington, Wen Shi Lee, Hyon-Xhi Tan, Thomas P. Davis, Nghia P. Truong, Stephen J. Kent, Adam K. Wheatley

Summary: Using monoclonal antibodies to target vaccine antigens to specific immune cells within lymph nodes can enhance immune responses. The authors developed a system using self-assembling ferritin nanoparticles to attach antibodies to the nanoparticles, allowing for rapid screening of different targeting antibodies. By targeting Clec9a, the authors observed higher antibody titers and increased germinal center formation, leading to robust antibody responses. However, the effectiveness of immune cell targeting depends on the antigen, with variation observed for different immunogens.

ADVANCED HEALTHCARE MATERIALS (2023)

Article Medicine, General & Internal

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine

Georgia Deliyannis, Nicholas A. Gherardin, Chinn Yi Wong, Samantha L. Grimley, James P. Cooney, Samuel J. Redmond, Paula Ellenberg, Kathryn C. Davidson, Francesca L. Mordant, Tim Smith, Marianne Gillard, Ester Lopez, Julie McAuley, Chee Wah Tan, Jing J. Wang, Weiguang Zeng, Mason Littlejohn, Runhong Zhou, Jasper Fuk-Woo Chan, Zhi-wei Chen, Airn E. Hartwig, Richard Bowen, Jason M. Mackenzie, Elizabeth Vincan, Joseph Torresi, Katherine Kedzierska, Colin W. Pouton, Tom P. Gordon, Lin-fa Wang, Stephen J. Kent, Adam K. Wheatley, Sharon R. Lewin, Kanta Subbarao, Amy W. Chung, Marc Pellegrini, Trent Munro, Terry Nolan, Steven Rockman, David C. Jackson, Damian F. J. Purcell, Dale I. Godfrey

Summary: Researchers have developed a protein subunit vaccine to address the variants of the SARS-CoV-2 virus. The vaccine induces strong neutralizing antibody responses and provides durable immunity against upper and lower airway infections. It has the potential to complement existing vaccines and is currently in a phase I clinical trial.

EBIOMEDICINE (2023)

Article Multidisciplinary Sciences

Monoclonal antibody levels and protection from COVID-19

Eva Stadler, Martin T. Burgess, Timothy E. Schlub, Shanchita R. Khan, Khai Li Chai, Zoe K. McQuilten, Erica M. Wood, Mark N. Polizzotto, Stephen J. Kent, Deborah Cromer, Miles P. Davenport, David S. Khoury

Summary: Multiple monoclonal antibodies have been effective for both prophylaxis and therapy for SARS-CoV-2 infection. This study aggregates data from randomized controlled trials to model the dose-response relationship of monoclonal antibodies for prophylaxis. The estimated 50% protection from COVID-19 is achieved with a concentration of 96-fold of the in vitro IC50.

NATURE COMMUNICATIONS (2023)

Article Immunology

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection

David S. Khoury, Timothy E. Schlub, Deborah Cromer, Megan Steain, Youyi Fong, Peter B. Gilbert, Kanta Subbarao, James A. Triccas, Stephen J. Kent, Miles P. Davenport

Summary: Multiple studies have demonstrated a correlation between neutralizing antibody levels and protection from COVID-19, estimating the relationship between the two. However, estimates of the required level of neutralizing antibodies for protection vary across these studies. By normalizing antibody titers, it has been found that there is a consistent relationship between antibody levels and protection from COVID-19. This finding is crucial for future vaccine planning, assessing population immunity, and mitigating the global impact of the COVID-19 pandemic.

EMERGING INFECTIOUS DISEASES (2023)

Article Immunology

Antibody glycosylation correlates with disease progression in SIV-Mycobacterium tuberculosis coinfected cynomolgus macaques

Ebene R. Haycroft, Timon Damelang, Ester Lopez, Mark A. Rodgers, Bruce D. Wines, Mark Hogarth, Cassaundra L. Ameel, Stephen J. Kent, Charles A. Scanga, Shelby L. O'Connor, Amy W. Chung

Summary: This study used a macaque model of tuberculosis and HIV co-infection to investigate the humoral responses. They found that antibody responses to tuberculosis were impaired during HIV co-infection. The study suggests that humoral immunity and antibody glycosylation may play a role in the control and progression of tuberculosis.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2023)

No Data Available